Phio announces dosing of first patient in trial with AgonOx, Providence Cancer

Phio Pharmaceuticals announced that its clinical development partners, AgonOx and Providence Cancer Institute of Oregon, have dosed their first patient in an Adoptive Cell Therapy clinical trial. This first-in-human trial is investigating the safety and the potential for enhanced therapeutic benefit from the administration of AgonOx’s AGX148 ‘double positive’ CD8 tumor-infiltrating lymphocytes alone and in combination with Phio‘s PD-1 silencing PH-762 in patients with melanoma and other advanced solid tumors. “TIL therapies hold the promise of clinical benefit in patients with solid malignancies. This product is different from current TIL therapies as we are selectively expanding the tumor-reactive T cells and potentially increasing their potency by reducing PD-1 suppression,” said Andrew Weinberg, Ph.D., Founder and CSO of AgonOx, Inc., and Judith Ann Hartmann Endowed Chair for the Laboratory of Basic Immunology at the Earle A. Chiles Research Institute.